CytoCore Hires Silicon Valley PR Firm for New Uterine Cancer Scan.

Ground-breaking Early Detection Designed to Save Thousands of Lives

CHICAGO -- CytoCore Inc. (OTCBB:CYCR), a late-stage bio-scientific research company, has engaged a leading Bay Area public relations firm to help platform and launch a reliable, cost-effective, first-ever early detection test for uterine/endometrial cancers.

With two decades of experience supporting emerging technologies, SIPR's strategic campaign experience will advance CytoCore's product portfolio, which includes the e2 Collector, a unique cell collection device for the Pap test that is being readied for manufacturing, and the groundbreaking new InPath[TM] System, a highly accurate cancer scan designed to prevent deaths through early diagnosis of the more than 40,000 cases of uterine cancer reported every year.

"We believe SIPR's depth of experience with Silicon Valley's innovation technologies - and, in particular, the regulated life sciences -- makes them uniquely capable of delivering the right message to the right market segments at the right time," said Dr. David Weisberg, CytoCore's CEO. "We're very excited about entering this next phase of development with SIPR as a support partner to advise and guide us in this most critical business area."

CytoCore's new InPath[TM] System uterine and endometrial cancer scan, whose unusually high degree of accuracy is based on the unique new P2X7 biomarker, will for the first time help women at risk detect uterine cancers and pre-cancers in their earliest stages. With an estimated price at about $100 per test, the company expects many millions of women eventually will incorporate the uterine screening in their regular preventative health care routine.

SIPR's healthcare team has a depth of experience with marketing campaigns for many of today's most recognized drug brands and promoting research for some of the country's most prestigious medical institutions.

For more information about SIPR, visit: www.sipr.com

For more information about CytoCore, visit: www.CytocoreInc.com

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.